{"page":{"totalFilteredElements":39},"studies":[{"active":true,"description":"Establishment of a national registry for the Evaluation and improvement of Risk-adjusted prevention for hereditary breast and ovarian cancer","eudractNumber":null,"id":6724,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2021-01-01T13:47:32+01:00","shortTitle":"HerediCaRe","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Wechselseitiger Patienten -Arzt-Austausch in der Versorgung bei Brustkrebs mit dem Ziel der gemeinsamen Erarbeitung neuer Patienten-orientierter Strukturen.","eudractNumber":null,"id":12056,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-03-30T08:24:39+02:00","shortTitle":"Hi WAVES","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with with primary high-risk lobular breast cancer - LOBSTER","eudractNumber":"2023-509292-17-00","id":9924,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06607757","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-12-11T11:29:15+01:00","shortTitle":"LOBSTER","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"A Prospective Non-interventional Multicenter Cohort Study to Evaluate Different Imaging-guided Methods for Localization of Non-palpable Malignant Breast Lesions [EUBREAST-4]","eudractNumber":null,"id":10597,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05559411","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-06-24T10:21:40+02:00","shortTitle":"MELODY / EUBREAST-4","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer with focos on digital side effect management","eudractNumber":"2021-000287-30","id":8045,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"ER+","id":"mt_47"},{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"PgR+","id":"mt_49"}],"nctNumber":"NCT05362760","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2022-12-01T13:42:29+01:00","shortTitle":"Minerva","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Comprehensive assessment of clinical features and biomarkers to \nidentify patients with advanced or metastatic breast cancer for \nmarker driven trials in humans (CATCH).","eudractNumber":null,"id":10013,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05652569","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-08-08T09:15:42+02:00","shortTitle":"NCT-Studie: CATCH","therapeutical":true,"therapyLines":[{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with <u>early breast cancer</u> for enrolment on marker driven trials (COGNITION)","eudractNumber":null,"id":9308,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05906407","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-01-08T09:19:05+01:00","shortTitle":"NCT-Studie: COGNITION","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"&#160;COGNITION-GUIDE&#160;Genomics guided targeted post-neoadjuvant therapy in patients with&#160;early breast cancer- a multicenter, open-label, umbrella phase -II study<div>2020-002606-22 ( EudraCT Number )</div>","eudractNumber":"2024-514022-23-00","id":11293,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05332561","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-04T08:25:34+02:00","shortTitle":"NCT-Studie: COGNITION-Guide","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumors","eudractNumber":"2024-512019-36","id":10837,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"ROR 1","id":"mt_288"}],"nctNumber":null,"phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2025-04-09T09:39:02+02:00","shortTitle":"NCT-Studie: LION 1","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"<p class=\"MsoNormal\" style=\"line-height:normal;\">National Center for Tumor Diseases / German Cancer Consortium (NCT/DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER)</p><p class=\"MsoNormal\" style=\"line-height:normal;\"><b>NCT MASTER Program</b></p>","eudractNumber":null,"id":4421,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T12:10:57+01:00","shortTitle":"NCT-Studie: MASTER Programm","therapeutical":true,"therapyLines":[]}]}